Literature DB >> 29511838

The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma.

Soyoung Kim1, Dongwoo Kim1, Se Hoon Kim2, Mi-Ae Park3, Jong Hee Chang4, Mijin Yun5.   

Abstract

PURPOSE: This prospective study aimed to evaluate the clinical values of 11C-acetate positron emission tomography/computed tomography (PET/CT) in predicting histologic grades and survival in patients with cerebral glioma.
METHODS: Seventy-three patients with surgically confirmed cerebral gliomas (19 grade II, 21 grade III, and 33 grade IV) who underwent 11C-acetate PET/CT before surgery were included. Tumor-to-choroid plexus ratio (TCR), which was defined as the maximum standardized uptake value (SUV) of tumors to the mean SUV of choroid plexus, was compared between three World Health Organization (WHO) grade groups. Moreover, metabolic tumor volumes (MTV) were calculated. Progression-free survival (PFS) and overall survival (OS) curves were plotted using the Kaplan-Meier method, and differences in survival between groups were assessed using the log-rank test.
RESULTS: Median TCR was 1.20 (interquartile range [IQR], 1.14 to 1.4) in grade II, 1.65 (IQR, 1.26 to 1.79) in grade III, and 2.53 (IQR, 1.93 to 3.30) in grade IV gliomas. Significant differences in TCR were seen among the three WHO grade groups (P < 0.001). In Cox regression analysis including TCR, MTV, molecular markers, and other clinical factors, TCR was prognostic for PFS (P = 0.016) and TCR and MTV were prognostic for OS (P = 0.024 [TCR], P = 0.030 [MTV]). PFS and OS were significantly shorter in patients with a TCR ≥ 1.6 than in those with a TCR < 1.6. OS were significantly shorter in patients with a MTV ≥ 1 than in those with a TCR < 1.
CONCLUSIONS: TCR on 11C-acetate PET/CT significantly differed between low- and high-grade cerebral gliomas, and it showed the capability to further differentiate grade III from grade IV tumors. TCR and MTV were independent prognostic factors and predicted survival better than did the WHO grade.

Entities:  

Keywords:  Acetate; Glioma; Grading; Positron emission tomography; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 29511838     DOI: 10.1007/s00259-018-3948-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  23 in total

1.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordonna Fulop; Max Liu; Rachel Blanda; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-10-27       Impact factor: 12.300

2.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.

Authors:  Osamu Manabe; Naoya Hattori; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Tohru Shiga; Keiichi Magota; Noriko Oyama-Manabe; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Preferential labeling of glial and meningial brain tumors with [2-(14)C]acetate.

Authors:  G A Dienel; D Popp; P D Drew; K Ball; A Krisht; N F Cruz
Journal:  J Nucl Med       Date:  2001-08       Impact factor: 10.057

5.  PET imaging of brain astrocytoma with 1-11C-acetate.

Authors:  Ren-Shyan Liu; Cheng-Pei Chang; Lee-Shing Chu; Yum-Kung Chu; Hung-Jen Hsieh; Chi-Wei Chang; Bang-Hung Yang; Shan-Hui Yen; Min-Chao Huang; Su-Quin Liao; Shin-Hwa Yeh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-11       Impact factor: 9.236

6.  11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.

Authors:  Chi-Lai Ho; Simon C H Yu; David W C Yeung
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

7.  Preferential utilization of acetate by astrocytes is attributable to transport.

Authors:  R A Waniewski; D L Martin
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

8.  Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET.

Authors:  Tatsuro Tsuchida; Hiroaki Takeuchi; Hidehiko Okazawa; Tetsuya Tsujikawa; Yasuhisa Fujibayashi
Journal:  Nucl Med Biol       Date:  2008-02       Impact factor: 2.408

9.  Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas.

Authors:  Keisuke Miyake; Aya Shinomiya; Masaki Okada; Tetsuhiro Hatakeyama; Nobuyuki Kawai; Takashi Tamiya
Journal:  J Biomed Biotechnol       Date:  2012-04-11

10.  Imaging Spectrum and Pitfalls of (11)C-Methionine Positron Emission Tomography in a Series of Patients with Intracranial Lesions.

Authors:  Kimiteru Ito; Hiroshi Matsuda; Kazoo Kubota
Journal:  Korean J Radiol       Date:  2016-04-14       Impact factor: 3.500

View more
  10 in total

Review 1.  60 Years of Achievements by KSNM in Neuroimaging Research.

Authors:  Jae Seung Kim; Hye Joo Son; Minyoung Oh; Dong Yun Lee; Hae Won Kim; Jungsu Oh
Journal:  Nucl Med Mol Imaging       Date:  2022-01-15

Review 2.  Acetyl-CoA Synthetase 2 as a Therapeutic Target in Tumor Metabolism.

Authors:  Mengfang Liu; Na Liu; Jinlei Wang; Shengqiao Fu; Xu Wang; Deyu Chen
Journal:  Cancers (Basel)       Date:  2022-06-12       Impact factor: 6.575

3.  Increased 14C-acetate accumulation in IDH-mutated human glioblastoma: implications for detecting IDH-mutated glioblastoma with 11C-acetate PET imaging.

Authors:  Sho Koyasu; Yoichi Shimizu; Akiyo Morinibu; Tsuneo Saga; Yuji Nakamoto; Kaori Togashi; Hiroshi Harada
Journal:  J Neurooncol       Date:  2019-10-30       Impact factor: 4.130

4.  Choroid Plexus as the Best Reference Region for Standardized Uptake Value Analysis on C11-Acetate PET/CT for Grading and Predicting Prognosis in Patients with Cerebral Gliomas.

Authors:  Dongwoo Kim; Arthur Cho; Sang Hyun Hwang; KwanHyeong Jo; Jong Hee Chang; Mijin Yun
Journal:  Nucl Med Mol Imaging       Date:  2020-11-16

5.  Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth.

Authors:  Katelyn D Miller; Katherine Pniewski; Caroline E Perry; Sara B Papp; Joshua D Shaffer; Jesse N Velasco-Silva; Jessica C Casciano; Tomas M Aramburu; Yellamelli V V Srikanth; Joel Cassel; Emmanuel Skordalakes; Andrew V Kossenkov; Joseph M Salvino; Zachary T Schug
Journal:  Cancer Res       Date:  2021-01-07       Impact factor: 13.312

6.  11C-acetate PET/CT: a potential alternative of transcranial biopsy for grading cerebral gliomas.

Authors:  Jun Hatazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06       Impact factor: 9.236

Review 7.  The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors.

Authors:  Ilanah J Pruis; Guus A M S van Dongen; Sophie E M Veldhuijzen van Zanten
Journal:  Int J Mol Sci       Date:  2020-02-04       Impact factor: 5.923

Review 8.  Metabolite-derived protein modifications modulating oncogenic signaling.

Authors:  Yawen Liu; Anke Vandekeere; Min Xu; Sarah-Maria Fendt; Patricia Altea-Manzano
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

Review 9.  Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.

Authors:  Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

Review 10.  A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.

Authors:  Julie Bolcaen; Janke Kleynhans; Shankari Nair; Jeroen Verhoeven; Ingeborg Goethals; Mike Sathekge; Charlot Vandevoorde; Thomas Ebenhan
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.